Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BW-1010
- Development stage
- Phase 1
- Lead developer
- BlueWillow Biologics
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
**BW-1010** is an investigational intranasal anthrax vaccine developed by BlueWillow Biologics and Porton Biopharma. It combines recombinant *Bacillus anthracis* protective antigen with BlueWillow's W805EC/NE01 oil-in-water nanoemulsion adjuvant platform. Intranasal administration is intended to elicit both systemic neutralizing antibody responses and mucosal immunity, including nasal IgA and IgG responses, to protect against anthrax toxin-mediated disease following exposure to *Bacillus anthracis*. BW-1010 completed a Phase 1 study in healthy adults evaluating safety, tolerability, and immunogenicity.
- Other names
- NanoVax anthrax vaccine
02
Targets
PA (Influenza polymerase acidic protein)
Beyond the preview
Go deeper on BW-1010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BW-1010.